Skip to content
20-F/A

Annual Report (Foreign)

Altamira Therapeutics Ltd. CYTOF

0001213900-24-034940

← back to feed
Filed
Apr 22, 2024 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2023 · Dec 31, 2023 491.26K sh
Shares Diluted restated FY 2023 · Dec 31, 2022 45.54K sh
Shares Diluted restated FY 2023 · Dec 31, 2021 33.12K sh
Cash And Equivalents FY 2023 · Dec 31, 2023 617.41K
Cash And Equivalents FY 2023 · Dec 31, 2022 15.4K
Cash And Equivalents FY 2023 · Dec 31, 2021 984.19K
Cash And Equivalents FY 2023 · Dec 31, 2020 11.26M
Current Liabilities FY 2023 · Dec 31, 2023 888.91K
Current Liabilities FY 2023 · Dec 31, 2022 12.88M
Current Assets FY 2023 · Dec 31, 2023 1.22M
Current Assets FY 2023 · Dec 31, 2022 1.77M
Total Assets FY 2023 · Dec 31, 2023 7.69M
Total Assets FY 2023 · Dec 31, 2022 6.3M
Eps Diluted FY 2023 · Dec 31, 2023 −7.88
Eps Diluted restated FY 2023 · Dec 31, 2022 −582.58
Eps Diluted restated FY 2023 · Dec 31, 2021 −515.11
Eps Basic FY 2023 · Dec 31, 2023 −7.88
Eps Basic restated FY 2023 · Dec 31, 2022 −582.58
Eps Basic restated FY 2023 · Dec 31, 2021 −515.11
Operating Income FY 2023 · Dec 31, 2023 −5.92M
Operating Income restated FY 2023 · Dec 31, 2022 −18.01M
Operating Income restated FY 2023 · Dec 31, 2021 −6.87M
Cost Of Revenue FY 2023 · Dec 31, 2023 33.97K